Robo1-Specific Chimeric Antigen Receptor Natural Killer Cell Therapy For Pancreatic Ductal Adenocarcinoma With Liver Metastasis

We present a case of Robo1-specific chimeric antigen receptor natural killer (CAR-NK) cell therapy for pancreatic ductal adenocarcinoma with liver metastasis in a 46-year-old male. The patient was treated with Robo1-specific CAR-NK cell infusion. Liver metastasis was treated with percutaneous Robo1-specific CAR-NK Cell injection. In the 1st month, the patient received Robo1-CAR-NK intravenous injection on days 1 and 3 and percutaneous injection on days 2 and 4 every week, respectively, and the dosage administered was 1x10(9) Robo1- specific CAR-NK cell, respectively. The patient continuously received Robo1-CAR-NK intravenous injection once a week. An evaluation was conducted every 2 weeks. The patient was safely applied the therapy with no substantial adverse effects. Pancreatic lesion was controlled within 5 months. Karnofsky Performance Score and child stage of the patient did not change greatly during the therapy, and the patient's overall survival time was 8 months.